Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 720 DKK -1.1% Market Closed
Market Cap: 50.9B DKK
Have any thoughts about
Zealand Pharma A/S?
Write Note

Net Margin
Zealand Pharma A/S

-1 369.3%
Current
-813%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 369.3%
=
Net Income
-1.1B
/
Revenue
76.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
DK
Zealand Pharma A/S
CSE:ZEAL
50.9B DKK
-1 369%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country DK
Market Cap 50.9B DKK
Net Margin
-1 369%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 315.2B USD
Net Margin
9%
Country US
Market Cap 141.9B USD
Net Margin
13%
Country US
Market Cap 116.4B USD
Net Margin
0%
Country US
Market Cap 104.5B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Zealand Pharma A/S
Glance View

Market Cap
50.9B DKK
Industry
Biotechnology

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZEAL Intrinsic Value
201.52 DKK
Overvaluation 72%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 369.3%
=
Net Income
-1.1B
/
Revenue
76.9m
What is the Net Margin of Zealand Pharma A/S?

Based on Zealand Pharma A/S's most recent financial statements, the company has Net Margin of -1 369.3%.